These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20590856)

  • 1. Animal models of inhibitors.
    Reipert B; Arruda V; Lillicrap D
    Haemophilia; 2010 Jul; 16 Suppl 5():47-53. PubMed ID: 20590856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of inhibitors.
    Astermark J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urgent inhibitor issues: targets for expanded research.
    Hoots WK
    Haemophilia; 2006 Dec; 12 Suppl 6():107-13. PubMed ID: 17123403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory antibodies in hemophilia A.
    Pratt KP
    Curr Opin Hematol; 2012 Sep; 19(5):399-405. PubMed ID: 22814650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitor development in patients with hemophilia: an overview.
    Leissinger CA
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S1-2. PubMed ID: 16690370
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B
    Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
    van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
    Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitor development: patient-determined risk factors.
    Astermark J
    Haemophilia; 2010 May; 16(102):66-70. PubMed ID: 19298384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance induction in hemophilia: innovation and accomplishments.
    Sherman A; Biswas M; Herzog RW
    Curr Opin Hematol; 2018 Sep; 25(5):365-372. PubMed ID: 29994897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and prediction of inhibitor risk.
    Astermark J
    Haemophilia; 2012 Jul; 18 Suppl 4():38-42. PubMed ID: 22726081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 15. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 16. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies.
    Adair P; Su Y; Scott DW
    Discov Med; 2013 May; 15(84):275-82. PubMed ID: 23725600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of factor VIII in hemophilia.
    Lacroix-Desmazes S; Dimitrov JD; Repesse Y
    N Engl J Med; 2009 Jul; 361(3):308; author reply 310. PubMed ID: 19605840
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New predictive approaches for ITI treatment.
    Minno GD; Santagostino E; Pratt K; Königs C
    Haemophilia; 2014 Sep; 20 Suppl 6():27-43. PubMed ID: 24975702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.